In the face of pressure from sales of Pfizer Inc.'s Viagra oral compound for erectile dysfunction, Vivus Inc. has made an about-face on its strategy for marketing Muse alprostadil urethral suppository to treat ED. Rather than try to build a force to compete with Pfizer's marketing might, VVUS has dropped domestic sales of Muse and will look for a pharma partner that can match Pfizer.

At the same time, VVUS is marshalling its case for the use of Muse in situations where it can argue that Viagra isn't effective.